Cargando…
A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
Autores principales: | Zhou, Emily, Zhang, Baoyi, Zhu, Kenneth, Schaafsma, Evelien, Kumar, Runjun D., Cheng, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711082/ https://www.ncbi.nlm.nih.gov/pubmed/33377652 http://dx.doi.org/10.1002/ctm2.216 |
Ejemplares similares
-
Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer
por: Yun, Jae Won, et al.
Publicado: (2021) -
Immune checkpoint gene
VSIR
predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
por: Yao, Kevin, et al.
Publicado: (2022) -
Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer
por: Yao, Kevin, et al.
Publicado: (2022) -
Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017) -
5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)